HansBiomed (Korea) Performance
| 042520 Stock | KRW 7,750 60.00 0.78% |
The company retains a Market Volatility (i.e., Beta) of -0.47, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning HansBiomed are expected to decrease at a much lower rate. During the bear market, HansBiomed is likely to outperform the market. At this point, HansBiomed has a negative expected return of -0.42%. Please make sure to check out HansBiomed's coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if HansBiomed performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days HansBiomed has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | 3.2 B |
HansBiomed |
HansBiomed Relative Risk vs. Return Landscape
If you would invest 1,015,000 in HansBiomed on September 1, 2024 and sell it today you would lose (240,000) from holding HansBiomed or give up 23.65% of portfolio value over 90 days. HansBiomed is generating negative expected returns and assumes 2.5601% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than HansBiomed, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
HansBiomed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HansBiomed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as HansBiomed, and traders can use it to determine the average amount a HansBiomed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1625
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 042520 |
Estimated Market Risk
| 2.56 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average HansBiomed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HansBiomed by adding HansBiomed to a well-diversified portfolio.
HansBiomed Fundamentals Growth
HansBiomed Stock prices reflect investors' perceptions of the future prospects and financial health of HansBiomed, and HansBiomed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HansBiomed Stock performance.
| Return On Equity | 13.65 | |||
| Return On Asset | -0.0946 | |||
| Profit Margin | (0.31) % | |||
| Operating Margin | (0.33) % | |||
| Current Valuation | 184.7 B | |||
| Shares Outstanding | 8.95 M | |||
| Price To Earning | 38.44 X | |||
| Price To Sales | 1.46 X | |||
| Revenue | 74.46 B | |||
| EBITDA | (14.99 B) | |||
| Cash And Equivalents | 7.52 B | |||
| Total Debt | 1.35 B | |||
| Debt To Equity | 0.73 % | |||
| Cash Flow From Operations | (4.27 B) | |||
| Total Asset | 131.69 B | |||
| Retained Earnings | 23.23 B | |||
| Current Asset | 21.53 B | |||
| Current Liabilities | 6.41 B | |||
About HansBiomed Performance
By analyzing HansBiomed's fundamental ratios, stakeholders can gain valuable insights into HansBiomed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HansBiomed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HansBiomed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. HansBiomed Corporation was founded in 1993 and is based in Seoul, South Korea. HANS BIOMED is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about HansBiomed performance evaluation
Checking the ongoing alerts about HansBiomed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for HansBiomed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| HansBiomed generated a negative expected return over the last 90 days | |
| HansBiomed has accumulated about 7.52 B in cash with (4.27 B) of positive cash flow from operations. | |
| Roughly 28.0% of the company shares are owned by insiders or employees |
- Analyzing HansBiomed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HansBiomed's stock is overvalued or undervalued compared to its peers.
- Examining HansBiomed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HansBiomed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of HansBiomed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HansBiomed's stock. These opinions can provide insight into HansBiomed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HansBiomed Stock analysis
When running HansBiomed's price analysis, check to measure HansBiomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HansBiomed is operating at the current time. Most of HansBiomed's value examination focuses on studying past and present price action to predict the probability of HansBiomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HansBiomed's price. Additionally, you may evaluate how the addition of HansBiomed to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |